Biogen delivered strong fourth quarter and full year 2025 results, finishing slightly above the upper end of guidance with total revenue of $9.9 billion (up 2% year-over-year) and non-GAAP diluted EPS of $15.28. Growth products generated $3.3 billion in fiscal 2025, up 19%, with the four products launched since 2023 (Lekembi, Skyclaris, Xerxuve, and Calcadi) now generating over $1 billion in combined revenue. The MS business remained resilient at $3 billion in revenue. The company delivered $2.1 billion in free cash flow and ended the year with $4.2 billion in cash and marketable securities. Management highlighted significant pipeline expansion with 10 Phase III programs, up from just one in 2024. For 2026, the company provided guidance of non-GAAP diluted EPS of $15.25-$16.25, with total revenue expected to decline by mid-single digits due to MS franchise erosion, partially offset by growth products.
| Metric | Value | Change |
|---|---|---|
| Full Year 2025 Total Revenue | $9.9 billion | Up 2% year-over-year |
| Full Year 2025 Non-GAAP Diluted EPS | $15.28 | Above guidance |
| Q4 2025 Non-GAAP Diluted EPS | $1.99 | Above expectations |
| Growth Products Revenue (Full Year 2025) | $3.3 billion | Up 19% year-over-year |
| Free Cash Flow (Full Year 2025) | $2.1 billion | Strong cash generation |
| Cash and Marketable Securities | $4.2 billion | Strengthened balance sheet |
| Leqembi Q4 2025 Revenue | $134 million | Up 1054% versus Q3 2025 and Q4 2024 |
| Skyclaris Q4 2025 Revenue | $133 million | Up 30% year-over-year |
| SPINRAZA Q4 2025 Revenue | $356 million | Resilient performance |
| VUMERITY Full Year 2025 Revenue | $747 million | Up 19% year-over-year |
| Anti-CD20 Programs Q4 2025 Revenue | $521 million | Up 12% year-over-year |
| 2026 Non-GAAP Diluted EPS Guidance | $15.25 to $16.25 | Expected growth versus 2025 |
Biogen has successfully transformed its pipeline from a single late-stage asset (litifilumab) in 2024 to 10 Phase III programs today, representing a significant strategic pivot. This expansion includes high-conviction programs like litifilumab for lupus (with breakthrough therapy designation), frezelimab for AMR, and high-dose SPINRAZA. Management emphasized this transformation as evidence of their 'new Biogen' strategy, focusing on immunology and neuroscience. The accelerated timeline for litifilumab's TOPAZ-2 study (now reading end of 2026 instead of 2027) demonstrates execution capability and creates nearer-term value inflection points.
The company's growth products are outperforming with $3.3 billion in revenue (up 19%), now exceeding the MS business's $3 billion. This strategic shift toward growth products includes VUMERITY (now categorized as a growth product), Lekembi, Skyclaris, Xerxuve, and Calcadi. Management's decision to reclassify VUMERITY reflects their confidence in intelligent investments driving growth. The four products launched since 2023 have already surpassed $1 billion in combined revenue, demonstrating successful commercial execution in creating and penetrating new markets.
Lekembi maintains market leadership with over 60% of anti-amyloid therapy market share, positioning Biogen strongly in the Alzheimer's treatment landscape. The upcoming PDUFA decision for iClick subcutaneous initiation (May 24, 2026) represents a potential game-changer that could significantly expand the treatable population by reducing administration burden. Management highlighted that blood-based diagnostics have increased patient identification from 50% to 70%, and with 500,000 new Alzheimer's diagnoses annually but only 13,000 neurologists, the subcutaneous formulation could dramatically improve throughput and access.
Biogen is strategically expanding into rare immunology with litifilumab (lupus) and frezelimab (AMR), requiring new commercial capabilities in rheumatology and nephrology. Management is building these capabilities through targeted hiring and pre-launch investments, noting they've successfully attracted talent from companies with established presence in these areas. This expansion represents a strategic diversification beyond neuroscience, with management noting immunology offers cost-efficient development opportunities as safety-validated mechanisms can be applied across multiple indications.
The company is actively pursuing business development with recent collaborations (Vanqua, Dara Therapeutics) and acquisitions (Alcion Therapeutics). Management indicated they're looking for acquisitions in the $5-6 billion range of companies post-Phase III or early commercialization, though they've been selective due to valuation concerns. The Alcion acquisition specifically enhances their delivery capabilities, potentially improving the patient experience for SPINRAZA by replacing intrathecal administration with more convenient subcutaneous delivery.
International expansion remains a strategic priority, with selective European rollouts based on pricing assessments. Management noted they're taking a targeted approach to European launches (3-4 countries initially rather than pan-European) due to pricing and MFN (Most Favored Nation) considerations. For Skyclaris, the Brazil launch represents a significant opportunity in Friedreich's ataxia, while high-dose SPINRAZA has shown promising early adoption in Japan with better-than-expected uptake and switchbacks.
Biogen is maintaining financial discipline while investing for growth, with core OpEx expected to remain roughly consistent between 2025 and 2026 despite significant pre-launch investments. The company delivered $2.1 billion in free cash flow and ended with $4.2 billion in cash and marketable securities, providing financial flexibility. Management emphasized their strategy of reallocating resources from legacy businesses to growth products, demonstrating disciplined capital allocation while positioning for future growth.
Biogen expects total revenue to decline by mid-single digits in 2026, with MS product revenue (excluding VUMERITY) projected to decline by mid-teens. This represents significant ongoing pressure on the company's largest franchise, with TECFIDERA facing generic erosion in Europe and new biosimilar competition for Tysabri. Management acknowledged they're still determining the erosion rate for Tysabri following the biosimilar introduction, creating uncertainty around the company's revenue trajectory and ability to return to growth.
The company's return to top-line growth remains uncertain and dependent on successful Phase III readouts and launches that won't occur until 2027-2028 at the earliest. Management indicated that litifilumab (SLE) and frezelimab (AMR) could launch in 2028 if Phase III results are positive, meaning meaningful revenue contributions are still 2+ years away. This extended timeline creates a significant growth gap that business development would need to fill, though management noted difficulty finding attractively priced acquisitions.
Pipeline execution risk remains elevated with multiple critical Phase III readouts in 2026-2027, including litifilumab in SLE (end of 2026), frezelimab in AMR (2027), and BIB080 in Alzheimer's (mid-2026). Management acknowledged that 'nothing is ever given in research and development,' and the high-conviction designation doesn't guarantee success. The litifilumab program carries particular risk given mixed Phase II data and the historical challenges in developing lupus treatments.
Leqembi's growth trajectory faces reimbursement challenges, with full reimbursement for the iClick subcutaneous formulation not expected until January 1, 2027. Until then, patients must navigate formulary exemption processes, creating access barriers. Management acknowledged they don't have clear data on exemption success rates, though anecdotal evidence suggests high approval rates. This reimbursement uncertainty could slow adoption of the potentially game-changing subcutaneous formulation.
The company's early-stage pipeline remains thin relative to its late-stage portfolio, with management acknowledging they 'do need to build up our earlier stage pipeline.' While they've added some assets like BTK degrader (BI145) and anti-tau ASO (BIB080), the company appears to have limited capacity for high-risk, early-stage research. This creates a potential pipeline gap beyond the current wave of late-stage assets, particularly if some of these programs fail.
Significant pre-launch investments for litifilumab and frezelimab are impacting margins, with Q1 2026 expenses expected to be 10% higher than Q1 2025 due to phasing of these investments. While management maintains core OpEx will be consistent year-over-year, these investments increase the company's burn rate and create pressure for successful commercial execution. The need to build new commercial capabilities in rheumatology and nephrology also carries execution risk and could require sustained investment.
Management's guidance for 2026 includes considerable uncertainty around MS franchise erosion rates, particularly for Tysabri following biosimilar introduction. While they expressed optimism about maintaining share due to strong physician belief in the product and robust patient services, they acknowledged it's 'early days yet' to determine erosion rates. This uncertainty makes it difficult to model the company's financial performance with precision, particularly given the significant contribution of MS products to overall revenue.
Overall: Management displayed confidence and optimism throughout the call, emphasizing the company's strong commercial execution and pipeline transformation. Christopher Viehbacher (CEO) spoke with conviction about the company's progress, using phrases like 'functioning and firing on all cylinders' and 'very satisfactory manner.' The tone remained consistent between prepared remarks and Q&A, with management providing detailed responses to analyst questions while acknowledging uncertainties around pipeline execution and timing.
Confidence: HIGH - Management demonstrated high confidence in their commercial execution, pipeline strategy, and future growth prospects. They spoke with specificity about product performance, pipeline milestones, and strategic direction. The confidence was particularly evident in discussions about their late-stage pipeline and the potential of their growth products to offset MS franchise declines.
Management provided guidance of $15.25 to $16.25 for full year 2026, representing growth versus the full year 2025 result of $15.28. This guidance reflects confidence in the company's ability to grow earnings despite expected revenue declines, driven by disciplined expense management and operational efficiencies. The guidance assumes successful execution of the company's strategic priorities and continued strong commercial performance of growth products.
Total revenue is expected to decline by a mid-single digit percentage for 2026 compared to 2025. This decline reflects competitive pressures in the MS franchise, partially offset by increased revenue from growth products. Management specifically expects MS product revenue (excluding VUMERITY) to decline by a mid-teens percentage versus 2025, driven by generic erosion of TECFIDERA in Europe and biosimilar competition for Tysabri.
Management expects contract manufacturing revenue to be roughly $300 million in each half of 2026, providing visibility into this revenue stream. This guidance suggests stability in the contract manufacturing business, which provides a foundation of predictable revenue.
Gross margin is expected to be roughly consistent with 2025 levels, indicating that the company has stabilized its cost structure despite revenue pressures. This consistency reflects manufacturing efficiencies and favorable product mix as growth products continue to gain scale.
Core operating expenses are expected to remain roughly consistent with 2025 levels, demonstrating disciplined financial management despite significant pre-launch investments for litifilumab and frezelimab. However, Q1 expenses are expected to be approximately 10% higher than Q1 2025 due to phasing of investments in the lupus and nephrology portfolios.
Hedging & Uncertainty: Management employed moderate hedging throughout the call, particularly around pipeline outcomes and future growth timelines. Common hedging phrases included 'hopefully,' 'potentially,' 'could be,' and 'I think,' which appeared frequently in discussions of pipeline assets and future commercial performance. For example, Viehbacher stated, 'hopefully, the approval of the iClick' and 'we think that the iClick could actually, act create a whole new opportunity.' This hedging reflects appropriate caution given the inherent uncertainties in drug development and market adoption. However, management was notably less hedged when discussing current commercial performance, using more definitive language like 'functioning and firing on all cylinders' and 'very satisfactory manner.' The contrast between confident language around current operations and hedged language around future prospects suggests management is confident in execution but appropriately cautious about predicting outcomes in areas outside their control.
"From a commercial performance point of view, I think Biogen is functioning and firing on all cylinders, and doing very well." - Christopher Viehbacher, CEO
"I think the big story of 2025 is really the advance we've made in our pipeline." - Christopher Viehbacher, CEO
"We believe the transformation activities we have taken so far have established a strong foundation to deliver on the vision of the new Biogen." - Robin Kramer, CFO
"I'm really encouraged by the progress that we've made to rebuild and transform our development pipeline." - Priya Singhal, Head of Development
"We finished the year strongly with a very good fourth quarter, and I think finished the year in a very satisfactory manner." - Christopher Viehbacher, CEO
"We expect full year non-GAAP diluted EPS to be between $15.25 and $16.25 reflecting growth versus our full year 2025 results." - Robin Kramer, CFO
"Total revenue is expected to decline by a mid single digit percentage for 2026 compared to 2025." - Robin Kramer, CFO
"I think to really return to growth, I think there's two things really need to happen. One is we do need to start seeing the positive Phase III results come out and the launch of products." - Christopher Viehbacher, CEO
"We're generating cash. We're generating profits. And we're investing significantly in our growth brands." - Christopher Viehbacher, CEO
"We remain focused on broadening our early stage pipeline from both internal research assets and potentially business development opportunities." - Priya Singhal, Head of Development
Analyst Sentiment: Analysts displayed cautious optimism with focused questioning on execution timelines, pipeline strategy, and the path to return to growth. Key analysts including Alex Hammond (Wolfe Research), Phil Nadeau (TD Cowen), and Salveen Richter (Goldman Sachs) probed deeply into specific catalysts and risk factors. Questions were generally constructive but thorough, with analysts seeking clarity on the commercial opportunity for pipeline assets and the sustainability of current growth trends. There was particular interest in the Alzheimer's franchise (Leqembi and BIB080) and the immunology pipeline (litifilumab and frezelimab).
Management Responses: Management provided detailed, direct responses to analyst questions, demonstrating deep knowledge of their businesses and pipeline. Christopher Viehbacher (CEO) was particularly forthcoming in discussing strategic rationale and commercial considerations, while Priya Singhal (Head of Development) provided scientific context for pipeline decisions. Robin Kramer (CFO) offered clear financial guidance and capital allocation philosophy. Management did not appear defensive, even when pressed on challenging topics like MS franchise erosion or pipeline risks. They acknowledged uncertainties where appropriate while maintaining confidence in their overall strategy.
Leqembi Growth Trajectory and iClick Potential: Analysts sought clarity on the cadence of Leqembi sales growth, particularly around the maintenance induction split and the potential impact of subcutaneous formulation approval. Management explained that approximately 70% of patients persist to maintenance, with the iClick for induction representing a potential game-changer that could accelerate growth in late 2026 and into 2027, particularly once full reimbursement is achieved on January 1, 2027.
Return to Top-Line Growth Timeline: Multiple analysts questioned when Biogen's revenue would return to growth, given the expected MS franchise decline. Management indicated that meaningful growth would likely require successful Phase III readouts and launches of litifilumab (potentially 2028) and frezelimab (potentially 2028), or strategic business development acquisitions. They acknowledged the challenge of finding attractively priced acquisitions in the current market.
Pipeline Strategy and Risk Assessment: Analysts probed the scientific rationale and risk profile of key pipeline assets, particularly BIB080 (anti-tau ASO) and litifilumab. Management provided detailed scientific explanations for their high-conviction stance, emphasizing the strong biological rationale and encouraging early data. They acknowledged the inherent risks of drug development while expressing confidence in their target selection and trial design.
SPINRAZA High Dose Commercial Opportunity: Analysts sought details on the potential impact of high-dose SPINRAZA approval in the U.S. (April 2026 PDUFA). Management shared encouraging early data from Japan showing better-than-expected adoption and switchbacks, suggesting the enhanced efficacy profile could drive market share gains versus oral competitors, though they noted the need to wait for actual commercial data.
Commercial Infrastructure and Investment: Analysts questioned the level of investment required to build commercial capabilities in new therapeutic areas (rheumatology, nephrology). Management explained their strategy of targeted hiring and capability building, noting they don't expect a major change in overall OpEx trajectory as they reallocate resources from legacy businesses to growth products.
Capital Allocation Priorities: Analysts asked about potential share buybacks given the strengthened balance sheet. Management indicated they're primarily focused on deploying capital toward business development and growth investments, though share buybacks remain under consideration. They emphasized creating long-term shareholder value over immediate returns of capital.
Biogen is executing a strategic transformation from an MS-focused company to a diversified neuroscience and immunology player. The company has made significant progress in rebuilding its pipeline, expanding from one late-stage asset in 2024 to 10 Phase III programs today. Commercial execution remains strong, with growth products generating $3.3 billion (up 19%) and now exceeding the MS business's $3 billion in revenue. The company's financial position is solid, with $4.2 billion in cash and marketable securities and $2.1 billion of free cash flow. Key growth drivers include: (1) Leqembi's market leadership in Alzheimer's with potential acceleration from subcutaneous formulation approval in May 2026; (2) High-dose SPINRAZA launch showing promising early adoption in Japan; (3) Xerxuve's rapid growth in postpartum depression; (4) Skyclaris expansion in Friedreich's ataxia; and (5) Potential launches of litifilumab (lupus) and frezelimab (AMR) in 2028 if Phase III trials succeed. Critical factors for investment success include: (1) Successful execution of Phase III trials for litifilumab (SLE data end of 2026) and frezelimab (AMR data in 2027); (2) Leqembi subcutaneous approval and successful commercialization; (3) Managing MS franchise erosion while scaling growth products; (4) Strategic business development to fill growth gaps; and (5) Maintaining financial discipline while investing for future launches. Key metrics to monitor include: Leqembi prescription trends and market share, MS franchise revenue trends, pipeline readout results (particularly litifilumab SLE data in late 2026 and BIB080 Alzheimer's data in mid-2026), and free cash flow generation. Risks that could derail the thesis include: (1) Failure of key Phase III programs, particularly litifilumab and frezelimab; (2) Faster-than-expected MS franchise erosion; (3) Slower Leqembi adoption due to reimbursement or safety concerns; (4) Inability to find attractively priced acquisitions; and (5) Competitive threats in Alzheimer's and other key franchises. At current levels, Biogen appears fairly valued given the near-term revenue headwinds and extended timeline for pipeline contributions. The company is successfully building a bridge to growth, but investors need to see successful Phase III readouts and launches before the stock can significantly re-rate. The HOLD rating reflects this wait-and-see approach, acknowledging the company's progress while recognizing the execution risks that remain.
The Alzheimer's treatment landscape is undergoing a significant shift toward more efficient diagnostics, with blood-based tests increasing patient identification from 50% to 70%. This trend has broader implications for healthcare economics, as blood tests (~$140) replace more expensive diagnostics like PET scans (~$5,000) and lumbar punctures. Christopher Viehbacher noted, 'There's an economic reason for that too. A PET scan costs about $5,000. The cost of a test is, I think, somewhere around $140.' This shift toward more cost-effective diagnostics could expand the treatable patient population while reducing overall healthcare costs, representing a positive trend for the entire Alzheimer's ecosystem.
There's a growing recognition and treatment of rare diseases like postpartum depression and Friedreich's ataxia, driven by increased awareness and new treatment options. For postpartum depression, Viehbacher noted, 'approximately half a million mothers every year suffer from this, and only about 80,000 are diagnosed. And still fewer obviously treated on zirzube.' This significant underdiagnosis represents both a healthcare challenge and commercial opportunity. The success of Xerxuve, which 'more than doubled sales in 2025,' combined with public awareness efforts (Jennifer Lawrence, People Magazine features), suggests a broader trend toward addressing previously undertreated conditions.
The biopharma industry is facing increasing competitive pressures from biosimilars and generics, particularly in established franchises like MS. Biogen's experience with TECFIDERA generic erosion in Europe and new biosimilar competition for Tysabri reflects a broader industry trend of intensifying competition in mature therapeutic areas. Robin Kramer noted, 'TECFIDERA saw the expected acceleration of generic erosion in the EU, which we expect to continue in 2026.' This trend is forcing companies to accelerate innovation and diversify their portfolios, as Biogen has done by expanding into immunology and rare diseases.
The industry is seeing increased interest in immunology approaches that target specific immune pathways with potential applications across multiple indications. Priya Singhal noted, 'as you follow these immune pathways, you're gonna have a principal target. But once you have derisked the safety of that, it's relatively cost efficient to be able to go and do, signal seeking studies in other areas.' This approach allows companies to maximize R&D efficiency by developing platform technologies that can address multiple diseases, representing a positive trend for drug development productivity and potentially bringing treatments to underserved patient populations more quickly.